Response
n(%)
|
SP
N = 174
|
AS/SP
N = 182
|
Total
N = 356
|
P*
|
---|
Re-infection | 18 (10.3) | 9 (4.9) | 27 (7.6) | 0.054 |
Success (ACPR) | 138 (88.5) | 169 (97.7) | 307 (93.3) | 0.0008 |
Treatment failure | 18 (11.5) | 4 (2.3) | 22 (6.7) | 0.0008 |
   ETF | 5 (3.2) | 3 (1.7) | 8 (2.4) | 0.39 |
   LCF | 4 (2.6) | 0 | 4 (1.2) | 0.03 |
   LPF | 9 (5.8) | 1 (0.6) | 10 (3.0) | 0.006 |
- As patients with re-infection were withdrawn and rescued prior to study completion they are excluded form denominators for ACPR and treatment failure
- SP: sulphadoxine-pyrimethamine
- AS/SP: artesunate/sulphadoxine-pyrimethamine
- ACPR: adequate clinical and parasitological response
- ETF: early treatment failure
- LCF: late clinical failure
- LPF: late parasitological failure
- *2-sample test of proportions